GlassScriptPhysician profile
Andrew E Foster
NPI 1992057616
$2,293.64
in general payments reported to CMS, 2019-2025
19 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.37 · 2022: $232 · 2023: $596 · 2024: $921 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.09 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $665.79 | 2023-2025 | Lifevest |
| Amgen INC. | $289.78 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $225.71 | 2022-2024 | |
| Pfizer INC. | $202.18 | 2023-2025 | |
| Shockwave Medical, INC | $136.00 | 2022-2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $108.21 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $107.97 | 2025 | Nc Trek Neo, Pressurewire |
| Chiesi USA, INC. | $104.06 | 2022-2024 | Kengreal |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.38 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $59.92 | 2024 | Arcalyst |
| Heartflow, INC. | $44.37 | 2024-2025 | |
| Novo Nordisk INC | $40.80 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $33.71 | 2021-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $24.89 | 2025 | Winrevair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.88 | 2025 | Avvigo Guidance System |
| Lexicon Pharmaceuticals, INC. | $23.89 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $14.70 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $13.40 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.